About Us
Your Dream is our Vision: Life-saving medicines for life-threatening diseases
ViroPharma Incorporated is a multinational biotechnology company committed to developing and commercializing innovative products that address unmet medical needs.
Our current focus is to develop these products for physician specialists in hospital/transplant medicine, and gastroenterology, the branch of medicine dealing with the disorders affecting the digestive tract and associated organs.
In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.
Products and Pipeline
ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs.
Our lead clinical compound is Camvia™ (maribavir), an orally-administered antiviral Phase 3 drug in development for prevention of cytomegalovirus (CMV) disease in transplant patient;
Our marketed product, Vancocin® is the only antibiotic approved to treat two significant bacterial infections of the lower digestive tract. The product is administered orally and is indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile.
The company is also conducting research on non-toxigenic C. difficile (NTCD) with the goals of preventing the recurrence of disease following effective therapy for acute C. difficile infection (CDI) and preventing CDI in patients who are susceptible to colonization with toxigenic strains due to prior use of antibiotics. ViroPharma is also researching next generation antiviral compounds intended to target hepatitis C.
Corporate Goals
ViroPharma’s current clinical product portfolio serves as our foundation for growth, supported by revenues from sales of Vancocin; and we are expanding on our franchise areas, by capitalizing on business execution and prudent business development.
The values on which we have built our business are important assets to us: customer focus, quality, passion, continuous improvement, courage, teamwork and integrity. These values are evident throughout ViroPharma: the way we conduct our business, the way we communicate with our various customers, and in the manner in which we relate to one another.
At ViroPharma, we strive to improve healthcare by bringing new and important medicines to market.